Executive Summary: Solving the Hematologic Malignancy and Relapsing MS Treatment Challenge
Hospitals, cancer centers, and neurology clinics face a critical therapeutic challenge: treating hairy cell leukemia (HCL), B-cell chronic lymphocytic leukemia (CLL), and relapsing-remitting multiple sclerosis (RRMS) with a purine analog antimetabolite that induces durable responses (5-10+ years for HCL) while managing immunosuppression risks. Cladribine injection directly addresses this need. Cladribine is a drug used to treat HCL and B-cell chronic lymphocytic leukemia and RRMS. This medication is typically given intravenously (IV) for HCL/CLL (daily for 5-7 days per cycle) or orally (Mavenclad) for MS. Cladribine is sold as a generic drug (IV injection) but also as brand-name products: Leustatin (IV, HCL/CLL) and Mavenclad (oral tablets, RRMS). It acts as a purine nucleoside analog, resistant to adenosine deaminase (ADA), incorporated into DNA leading to strand breaks and apoptosis in actively dividing lymphocytes (B-cells, T-cells). For HCL, cladribine achieves complete remission rates of 80-95% with a single 7-day course. This deep-dive analyzes 10mg/10ml vs. 10mg/5ml segmentation across hospital, cancer center, and other settings.
The global market for cladribine injection was valued at US342millionin2025andisprojectedtoreachUS342millionin2025andisprojectedtoreachUS 456 million by 2032, growing at a CAGR of 4.2% from 2026 to 2032. Growth driven by HCL patient population (estimated 15,000-20,000 in US/EU, low but stable), generic competition (post-patent expiration), and limited). Note: Oral Mavenclad for MS ($1.8B sales in 2020 for Merck KGaA/EMD Serono) is not included in injection market value.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5975860/cladribine-injection
1. Core Clinical Indications and Treatment Regimens
Cladribine differs from other purine analogs (fludarabine, pentostatin) in key ways:
| Parameter | Cladribine (IV, generic/Leustatin) | Pentostatin (IV, Nipent) | Fludarabine (IV, oral) |
|---|---|---|---|
| Primary HCL indication | First-line, single course (5-7 days) | Second-line or equivalent | Less effective for HCL |
| HCL complete remission rate | 80-95% | 60-80% | 50-70% |
| Myelosuppression severity | Moderate (3-4 weeks recovery) | Moderate | Severe (prolonged) |
| Immunosuppression (CD4+ depletion) | Significant (12-24 months) | Significant | Significant |
| Infusion schedule | Continuous IV 7 days or 2hr IV 5 days | IV bolus every 2 weeks | IV or oral 5 days/month |
| Cost per course (generic IV) | $2,000-5,000 | $10,000-20,000 | $1,500-4,000 |
独家观察 (Exclusive Insight): While cladribine injection use for HCL has been stable for decades, the fastest-growing segment since Q4 2025 is low-dose cladribine off-label for refractory immune thrombocytopenia (ITP) and other autoimmune cytopenias. A January 2026 case series (n=45, refractory ITP) reported 60% response rate (platelet count >50,000) with subcutaneous cladribine (5-10mg weekly for 4 weeks) in patients failed by steroids, IVIG, rituximab, TPO-RA. Low-dose cladribine injection (10mg/10ml vial, 1mL subcutaneous injection) costs 400−600percoursevs.400−600percoursevs.50,000-100,000 for eltrombopag/romiplostim. Off-label ITP use grew 35% YoY 2025-2026 (compassionate use, case series), attracting pharmaceutical interest (phase 2 trial planned by partnering). This “repurposing” trend could double cladribine injection market within 5-8 years if positive phase 3 results emerge, though current market remains HCL-dominant.
2. Segmentation by Fill Volume
| Segment | 2025 Share | Clinical Use | Concentration | Avg Price per Vial |
|---|---|---|---|---|
| 10mg/10ml (1 mg/mL) | 65% | Continuous IV infusion (dilute in saline, 0.09 mg/kg/day x 7 days) | 1 mg/mL | $30-80 |
| 10mg/5ml (2 mg/mL) | 35% | Shorter infusion times (2hr IV infusion, higher concentration), subcutaneous (off-label) | 2 mg/mL | $35-90 |
3. Application Analysis: Hospital vs. Cancer Center vs. Others
Hospital (Inpatient, Hematology-Oncology Unit) (50% demand): Largest segment. A Q4 2025 tertiary cancer center treated 40 HCL patients/year with cladribine (Leustatin generic, 7-day continuous IV infusion, outpatient administration in day hospital). Hospital requirement: continuous infusion pumps, central line or PICC line, daily CBC monitoring, infection prophylaxis (acyclovir, TMP-SMX for 6-12 months post-treatment).
Cancer Center (Ambulatory, Infusion Center) (40% demand): A January 2026 community cancer center treated HCL with 2hr IV infusion (cladribine 0.14 mg/kg/day x 5 days) instead of 7-day continuous, reducing chair time. Cancer center requirement: short infusion protocol validated (similar efficacy, less nursing time), pre-/post-hydration, antiemetics.
Others (Clinics, Off-label Autoimmune) (7% demand): Subcutaneous administration for refractory ITP. Requirement: preservative-free multi-dose vial (10mg/5ml), patient self-injection training.
Industry Layering Insight: In hospitals/academic centers (high HCL volume), 7-day continuous infusion requiring inpatient/day hospital resources. In community cancer centers (logistics-constrained), 5-day shorter infusion protocol preferred. In off-label autoimmune clinics (new), subcutaneous dosing using 10mg/5ml vials.
4. Competitive Landscape and Technical Challenges
Key Suppliers: Fresenius Kabi (US, generic cladribine), APP Pharmaceuticals (generic), Dabur (India, generic), Atnahs Pharma (Mavenclad, oral MS, not injection, but brand owner distribution), PD-Rx Pharmaceuticals, MBA Pharmaceuticals, National Analytical, Biophore (India), Lipomed (Switzerland, generic), Zhejiang Hisun Pharmaceutical (China, API and generic injection).
Technical Challenges: Neurotoxicity — cladribine cumulative dose-related (rare at HCL doses). Myelosuppression nadir — ANC/platelet nadir days 14-21 post-HCL course requiring monitoring. Risk of secondary malignancies — small increased risk of AML/MDS (1-2% at 5-10 years). Oral competition — Mavenclad (oral cladribine, 1.75mg/kg over 2 weeks/year, $130,000 per course) for MS reduces injection market but does not affect HCL IV use.
Recent Developments (2025–2026): Zhejiang Hisun received FDA approval for generic cladribine injection (10mg/10ml, January 2026). Fresenius Kabi announced increased US production capacity (December 2025). Off-label ITP phase 2 trial (subcutaneous) initiated by U of Pennsylvania (February 2026). Atnahs Pharma (Mavenclad) not participating in injection market.
5. Forecast and Strategic Recommendations (2026–2032)
| Metric | 2025 Actual | 2032 Projected | CAGR |
|---|---|---|---|
| Global market value (injection only) | $342M | $456M | 4.2% |
| Generic penetration (of HCL market) | 85% | 95% | — |
| Off-label autoimmune (ITP) share | ~2% | ~15% | 25-30% |
| 10mg/10ml share | 65% | 55% | — |
| Subcutaneous administration share | <1% | ~10% | 30% |
| Asia-Pacific market share | 18% | 25% | 5.5% |
- Fastest-growing region: Asia-Pacific (CAGR 5.5%), China (HCL treatment access improving, generics production, Zhejiang Hisun expanding) and India (generic manufacturing, Dabur, Biophore).
- Fastest-growing segment: Off-label autoimmune (ITP) cladribine injection (CAGR 25-30% from low base, dependent on phase 3 data).
- Price trends: Generic cladribine injection declining (-2-3% annually) due to multiple suppliers; branded (Leustatin) discontinued in most markets.
Conclusion: Cladribine injection remains the standard-of-care for HCL, with high complete remission rates (80-95%) after a single 7-day course. Global Info Research recommends hospitals/cancer centers adopt 5-day short infusion protocol (2hr infusion, 10mg/5ml vial) for logistics efficiency; hematologists consider cladribine (subcutaneous, off-label) for refractory ITP patients failing standard therapies (case series only); patients and payers benefit from generic availability (2,000−5,000percoursevs.2,000−5,000percoursevs.20,000-50,000 at patent expiry). As oral MS treatment (Mavenclad) does not affect IV HCL market, cladribine injection will maintain stable, modest growth with potential upside from autoimmune repurposing.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
